Akcea Therapeutics (AKCA) Earning Somewhat Positive News Coverage, Accern Reports

Press coverage about Akcea Therapeutics (NASDAQ:AKCA) has been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akcea Therapeutics earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.1600306795269 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Several brokerages have recently commented on AKCA. BidaskClub cut shares of Akcea Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Zacks Investment Research cut shares of Akcea Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Stifel Nicolaus restated a “buy” rating and set a $20.00 price objective (up previously from $19.00) on shares of Akcea Therapeutics in a report on Tuesday, November 7th. Finally, Cowen restated a “buy” rating on shares of Akcea Therapeutics in a report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $22.75.

Shares of Akcea Therapeutics (NASDAQ:AKCA) traded down $0.21 on Friday, reaching $17.00. 147,759 shares of the company’s stock were exchanged, compared to its average volume of 333,519. Akcea Therapeutics has a 1 year low of $8.10 and a 1 year high of $31.23.

ILLEGAL ACTIVITY WARNING: “Akcea Therapeutics (AKCA) Earning Somewhat Positive News Coverage, Accern Reports” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/13/akcea-therapeutics-akca-getting-somewhat-positive-press-coverage-report-finds.html.

Akcea Therapeutics Company Profile

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Insider Buying and Selling by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply